
Alimera Sciences ALIM
Quarterly report 2024-Q2
added 08-07-2024
Alimera Sciences Total Shareholders Equity 2011-2025 | ALIM
Annual Total Shareholders Equity Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 46.2 M | -20.8 M | -2.6 M | -7.98 M | -4.44 M | 2.72 M | 14.9 M | 25.6 M | 26.3 M | 49.5 M | -4.92 M | 39.1 M | 25 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 49.5 M | -20.8 M | 14.5 M |
Quarterly Total Shareholders Equity Alimera Sciences
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.8 M | 40.7 M | 46.2 M | 46.2 M | -18.9 M | -20.8 M | -18.1 M | -12.3 M | -8.6 M | -2.6 M | 1.5 M | 5.89 M | -12 M | -7.98 M | -7.98 M | -7.98 M | -7.98 M | -4.44 M | -4.44 M | -4.44 M | -4.44 M | 2.72 M | 2.72 M | 2.72 M | 2.72 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 25.6 M | 25.6 M | 25.6 M | 25.6 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 49.5 M | 49.5 M | 49.5 M | 49.5 M | -4.92 M | -4.92 M | -4.92 M | -4.92 M | 39.1 M | 39.1 M | 39.1 M | 39.1 M | 25 M | 25 M | 25 M | 25 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.5 M | -20.8 M | 14.1 M |
Total Shareholders Equity of other stocks in the Drug manufacturers industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | ||
|
Canopy Growth Corporation
CGC
|
487 M | $ 1.21 | -7.63 % | $ 130 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
8 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-808 K | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | ||
|
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | ||
|
Aurora Cannabis
ACB
|
2.13 B | $ 4.47 | -2.08 % | $ 86.3 M | ||
|
DURECT Corporation
DRRX
|
14.8 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-6.6 B | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
1.01 B | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
557 M | - | 2.45 % | $ 38.1 M | ||
|
Emergent BioSolutions
EBS
|
649 M | $ 12.36 | -2.37 % | $ 633 M | ||
|
Athenex
ATNX
|
-6.51 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | $ 21.6 | 0.07 % | $ 2.06 B | ||
|
Evolus
EOLS
|
5.52 M | $ 6.88 | 0.36 % | $ 427 M | ||
|
Harrow Health
HROW
|
70.8 M | $ 50.08 | -0.16 % | $ 1.63 B | ||
|
China Pharma Holdings
CPHI
|
7.75 M | $ 1.29 | -1.56 % | $ 22.5 M | ||
|
Organogenesis Holdings
ORGO
|
263 M | $ 5.36 | -8.71 % | $ 706 M | ||
|
OrganiGram Holdings
OGI
|
300 M | $ 1.8 | 1.99 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
-1.02 B | $ 7.19 | -0.07 % | $ 2.62 B | ||
|
Pacira BioSciences
PCRX
|
778 M | $ 26.48 | 1.77 % | $ 1.22 B | ||
|
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | ||
|
Neoleukin Therapeutics
NLTX
|
186 M | - | - | $ 193 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
22.9 M | $ 4.11 | -2.14 % | $ 57.8 M | ||
|
Rockwell Medical
RMTI
|
21.3 M | $ 0.87 | 7.18 % | $ 20.3 M | ||
|
Solid Biosciences
SLDB
|
137 M | $ 5.83 | -1.19 % | $ 238 M | ||
|
Sundial Growers
SNDL
|
270 M | $ 1.75 | -1.13 % | $ 3.37 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 3.63 | -0.41 % | $ 4.5 M | ||
|
PetIQ
PETQ
|
223 M | - | 1.64 % | $ 400 M | ||
|
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | ||
|
Jupiter Wellness
JUPW
|
-2.17 M | - | - | $ 33.6 M | ||
|
Veru
VERU
|
32.3 M | $ 2.37 | 1.28 % | $ 320 M | ||
|
Perrigo Company plc
PRGO
|
4.32 B | $ 13.87 | 0.95 % | $ 1.91 B | ||
|
ProPhase Labs
PRPH
|
63.6 M | $ 0.51 | -16.94 % | $ 8.08 M | ||
|
Relmada Therapeutics
RLMD
|
85.4 M | $ 4.5 | -2.21 % | $ 135 M | ||
|
cbdMD
YCBD
|
1.96 M | $ 1.69 | 3.68 % | $ 7.29 M | ||
|
OptiNose
OPTN
|
-86.6 M | - | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
138 M | $ 9.92 | 0.22 % | $ 705 M | ||
|
PLx Pharma
PLXP
|
35.7 M | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
73 M | $ 0.58 | -1.87 % | $ 27.8 M | ||
|
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
3.32 B | $ 9.6 | -5.43 % | $ 5.93 B | ||
|
TherapeuticsMD
TXMD
|
29.3 M | $ 1.72 | 0.88 % | $ 18 M | ||
|
Viatris
VTRS
|
21.1 B | $ 12.33 | 0.69 % | $ 14.9 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M |